Obesity has been consistently associated with dementia. 4 key findings →
Design: longitudinal study Participants: 1,304 Evidence: moderate
Full summary, score breakdown and related studies → Original source Full text may need a subscription
28,180 Alzheimer's and dementia studies in plain English, each scored out of 100.
Obesity has been consistently associated with dementia. 4 key findings →
Design: longitudinal study Participants: 1,304 Evidence: moderate
Full summary, score breakdown and related studies → Original source Full text may need a subscription
A total of 8870 cases of all-cause dementia were observed over a median 13.9-year follow-up. 5 key findings →
Design: cohort study Participants: 782 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Of 736 patients (245 [33%] female, mean age 68·0 years [SD 11·2], median admission National Institutes of Health Stroke Scale (NIHSS) 3 [IQR 1-5]), 557 (76%) were followed up until death or the end of the study, and 706 (96%) contributed to the PSD analysis. 5 key findings →
Design: prospective cohort Participants: 736 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
A total of 1,979,509 participants (mean age, 49.0 years; 51.3% men; 50.7% with MetS) were included. 5 key findings →
Design: cohort study Participants: 1,979,509 Evidence: moderate
Full summary, score breakdown and related studies → Original source Full text may need a subscription
This study included 1526 early adult-life (mean [SD] age, 36.7 [4.7] years; 821 [53.8%] female), 1943 midlife (mean [SD] age, 54.0 [5.8] years; 1010 [52.0%] female), and 885 late-life (mean [SD] age, 71.0 [4.5] years; 473 [53.4%] female) participants. 5 key findings →
Design: cohort study Participants: 1,526 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Among 13 592 participants (mean [SD] age, 58.34 [9.39] years; 7175 [52.8%] female), 6525 (48.0%) experienced possible childhood loneliness, and 565 (4.2%) reported childhood loneliness. 5 key findings →
Design: cohort study Participants: 592 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
In the present study, higher adherence to MeDi was associated with a reduced risk for dementia and cognitive decline in a traditional Mediterranean population. 5 key findings →
Design: longitudinal study Participants: 62 Evidence: moderate
Full summary, score breakdown and related studies → Original source
Greater adherence to hPDI, MDS, RFS, and MIND was individually associated with larger brain volumes in specific regions. 5 key findings →
Design: cross-sectional Participants: 114,684 Evidence: low
Full summary, score breakdown and related studies → Original source
Blood-based biomarkers of AD/ADRD are influenced by common demographic and clinical characteristics. 2 key findings →
Participants: 779 Evidence: high
Full summary, score breakdown and related studies → Original source
This Dutch cohort study compared dementia rates in two groups of older adults enrolled ten years apart. 4 key findings →
Design: cohort Participants: 7,496 Evidence: preliminary
Full summary, score breakdown and related studies → Original source
Individuals with cannabis use severe enough to require hospital-based care were at increased risk of a new dementia diagnosis compared with those with all-cause hospital-based care or the general population. 5 key findings →
Design: cohort Participants: 6,086,794 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Given the inconsistent evidence regarding hearing aid use and reduced dementia risk, this study evaluates whether hearing aid use, particularly effective use, is associated with lower probable dementia risk among hearing-impaired older adults. 2 key findings →
Design: cohort Participants: 61,089 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
To evaluate reverse causation, we assessed whether a polygenic risk score for AD is associated with HGS. 5 key findings →
Design: cohort study Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
During 21 046 person-years of follow-up (median follow-up, 6.3 years), 199 women developed dementia, including 159 who developed AD. 5 key findings →
Design: cohort study Participants: 3,601 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
One hundred two (37.9%) participants were amyloid positive. 3 key findings →
Design: randomized controlled trial Participants: 269 Evidence: high
Full summary, score breakdown and related studies → Original source Full text may need a subscription
The CAIDE dementia and Framingham risk scores predict cognitive decline in late middle age but the Framingham risk scores may have an advantage over the dementia risk score for use in primary prevention for assessing risk of cognitive decline and targeting of modifiable risk factors. 3 key findings →
Design: cohort study Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Exercise at midlife may reduce the odds of dementia in older adulthood, suggesting that exercise interventions should be explored as a potential strategy for delaying disease onset. 3 key findings →
Design: case-control study Participants: 264 Evidence: moderate
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Mean age was 73.5 years and mean HbA1c was 6.8%. 3 key findings →
Design: cohort study Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
These findings underscore the importance of blood pressure control in midlife to mitigate dementia risk. 5 key findings →
Participants: 229,976 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
We have reported, for the first time, the dose-response relationship between LTPA and dementia, further supporting the international PA guideline from the standpoint of dementia prevention. 1 key finding →
Design: meta-analysis Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
Obesity in middle age increases the risk of future dementia independently of comorbid conditions. 3 key findings →
Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
We determined incidence and future projections of dementia after AIDS onset in 492 homosexual men with AIDS in the Baltimore/Los Angeles sites of the Multicenter AIDS Cohort Study, 64 of whom developed dementia. 3 key findings →
Design: cohort study Evidence: moderate
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Depressive symptoms in midlife or in late life are associated with an increased risk of developing dementia. 3 key findings →
Design: cohort study Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
During a mean follow-up of 12.1 years, 1,520 individuals developed dementia, 1,194 of whom had AD. 4 key findings →
Participants: 12,305 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Such AR estimates cannot be derived from the living population; rather they estimate the relative contribution of specific pathologies to dementia at death. 2 key findings →
Design: longitudinal study Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
10 of the 1,141 studies in this tag, picked by a fixed rule (a hash of each study's address), not by score or date; each page of this list shows a different 10. The same 10 appear here every time.
Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read
This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.
Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.
Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.
We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.
The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.
See the whole rubric drawn out → — four charts covering all 28,180 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.
This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 28,180 records, built mostly from automated pulls of Europe PMC (61.7% of the library) and OpenAlex (18.1%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.
1,034 records (3.7% of the library) are not peer-reviewed — 962 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.
See the full, machine-readable breakdown of this library's coverage →